CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
CEL-SCI Corporation (NYSE American: CVM), a Phase 3
cancer immunotherapy company, invites participants to pre-submit
questions for the Company’s upcoming Annual Shareholder Meeting to
be held on July 1, 2021 at 10:00 a.m. EDT. Questions can be
submitted up until 5:00 p.m. EDT on June 29, 2021. Please email
questions to email@example.com and use the subject line,
“CVM Call Questions” for this correspondence.
Questions received will be answered as the allotted meeting time
permits. After the business portion of the annual meeting concludes
and the meeting is adjourned, CEL-SCI will do its best to address
pre-submitted questions and reserves the right to exclude questions
that are not pertinent to annual meeting matters. We cannot ensure
that every shareholder who wishes to have a question or comment
addressed during the annual meeting will be able to do so in order
to conclude the meeting within a reasonable period of time.
Due to the concerns about the COVID-19 pandemic, CEL-SCI’s
annual meeting will be held as a hybrid meeting, both at 8229 Boone
Blvd., Suite 802, Vienna, VA 22182 and as a virtual meeting. To
attend the Annual Shareholder Meeting online go to
www.meetingcenter.io/281205077. We strongly advise you to attend
the meeting via the virtual annual shareholder meeting. You may not
be able to attend the meeting in person if space is not
About CEL-SCI Corporation
CEL-SCI is a clinical-stage biotechnology company focused on
finding the best way to activate the immune system to fight cancer
and infectious diseases. The Company’s lead investigational therapy
Multikine* is currently in a pivotal Phase 3 clinical trial
involving head and neck cancer, for which the Company has received
Orphan Drug Status from the FDA. The Company has operations in
Vienna, Virginia, and near Baltimore, Maryland.
This press release and statements made at the annual meeting may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Words when used in
this press release and at the annual meeting, such as "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K for the year
ended September 30, 2020. The Company undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in progress.
version on businesswire.com: https://www.businesswire.com/news/home/20210625005036/en/
Gavin de Windt CEL-SCI Corporation (703) 506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2021 to Sep 2021
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2020 to Sep 2021